BeiGene touts 'en­cour­ag­ing' re­sponse rates as the Chi­nese biotech mounts chal­lenge to BTK, PD-1 lead­ers

As BeiGene sets the stage for a piv­otal show­down with the OG BTK in­hibitor Im­bru­vi­ca, it’s ze­ro­ing in on a sub­set of pa­tients for whom …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.